人外周血活化淋巴细胞survivin基因的转录激活和表达相关的信号转导通路研究

Survivin是与细胞增殖和细胞凋亡调控密切相关的重要功能蛋白质,也是肿瘤临床诊断的分子标志物及治疗研究的理想靶标.由于发现人外周血活化淋巴细胞存在Survivin蛋白的显著表达,故以植物血凝素(PHA)和IL-2共刺激培养的正常人外周血单个核细胞为实验材料,采用RT-PCR、蛋白质印迹以及细胞周期分析等实验方法,观察淋巴细胞活化与Survivin蛋白表达之间的相互关系,并利用3种激酶抑制剂探索了淋巴细胞活化所致Survivin蛋白表达相关的信号转导通路.实验结果表明：人外周血单个核细胞在刺激培养36 h前后出现survivin基因的明显转录激活和蛋白质的起始表达,表达产物的水平随培养时间的延长而增加,且具有明显的细胞周期和周期时相依赖性.JAK2的抑制剂AG490阻断细胞周期的运行,且强烈抑制survivin基因的转录激活和蛋白质表达,PI3K和MEK的抑制剂Wortmannin和PD98059也有一定程度的抑制作用.所得实验结论是：survivin基因的转录激活和蛋白质表达与淋巴细胞活化相关联,代表细胞处在增殖状态.JAK2介导的JAK-STAT信号通路是淋巴细胞活化,Survivin蛋白表达必需和最重要的信号转导通路,PI3K和MEK介导的信号通路也具有一定的影响作用.     

凋亡抑制因子Survivin在大肠杆菌TB1中的表达纯化及鉴定

 本文旨在克隆凋亡抑制因子Survivin基因,并在大肠杆菌中进行可溶性表达与初步纯化. 采用RT-PCR法,扩增人凋亡抑制因子survivin cDNA,并克隆入原核表达载体pMAL p2X中,转化TB1大肠杆菌感受态细胞.经0.3 mmol/L IPTG诱导2 h后,收集菌体蛋白,进行SDS-PAGE、ELISA及Western 印迹鉴定. 实验获得凋亡抑制因子survivin编码区cDNA,以构建的原核表达载体pMAL-p2X survivin转化菌株后,可表达凋亡抑制因子survivin和麦芽糖结合蛋白(MBP)的融合蛋白,相对分子质量(Mr) 为58 000.并成功利用Factor Xa将融合蛋白裂解开.ELISA和Western 印迹表明,融合蛋白能与抗凋亡抑制因子survivin单克隆抗体特异性结合.获得的凋亡抑制因子survivin全长cDNA可在大肠杆菌TB1中以MBP survivin融合蛋白的形式表达,成功地将survivin目的蛋白和MBP蛋白分离,为深入研究survivin的结构和功能奠定了基础.     

Survivin基因RNA干扰对肺癌细胞凋亡及增殖的影响

目的:探讨Survivin表达对肺鳞癌细胞的凋亡和增殖的影响.方法:利用siRNA阻抑人肺鳞癌细胞内survivin基因的表达,用RT-PCR和Western Blotting法分析survivin基因mRNA和蛋白的表达,流式细胞术检测细胞凋亡率,细胞集落形成实验检测细胞增殖.结果:(1)Survivin在肺癌细胞中表达.转染Survivin siRNA可在RNA和蛋白水平阻断其表达;(2)转染Survivin siRNA的肺癌细胞凋亡率显著增加;(3)转染Survivin siRNA的肺癌细胞的集落形成率显著降低.结论:阻断Survivin表达可通过增加细胞凋亡率和降低细胞增殖增加肺鳞癌细胞的放疗敏感性.     

Survivin细胞核表达与上皮性卵巢癌预后的关系

目的:探讨上皮性卵巢癌survivin的亚细胞表达的临床意义.方法:应用免疫组化,检测64例上皮性卵巢癌中survivin蛋白的表达.分别计数survivin的细胞核表达和细胞质表达.分析Survivin表达与上皮性卵巢癌临床病理特征及患者预后的关系.结果:Survivin在上皮性卵巢癌中主要在细胞核表达(33.3%),明显高于survivin的细胞质表达率(15.8%)(p=0.001).Survivin细胞核表达阳性率与上皮性卵巢癌的组织学分级的增高、临床分期的提高、淋巴结转移阳性、PCNA表达增加和不良预后呈正相关(p＜0.05),但与上皮性卵巢癌患者的年龄(p=0.29)、组织学类型无关(p=0.739).多因素Cox比例风险回归模型分析显示survivin的细胞核表达是上皮性卵巢癌的独立预后因素(p＜0.01).结论:Survivin细胞核表达是预测上皮性卵巢癌不良预后的一个独立指标.     

褪黑素对胃癌小鼠Survivin表达的影响

目的探讨褪黑素对胃癌小鼠Survivin表达的影响。方法选用6-8周龄SPF级615近交系小鼠,接种胃癌MFC细胞,建立荷瘤小鼠模型并给予不同剂量的褪黑素处理,用Real-time PCR法和Western blot法检测肿瘤组织中Survivin mRNA和蛋白的表达。结果 Real-time PCR和Western-blot检测显示褪黑素各干预组小鼠胃癌组织中Survivin基因的表达水平下降且随褪黑素剂量增大而降低。结论褪黑素具有下调survivin的作用。褪黑素降低survivin的表达,可能是褪黑素抑制肿瘤的作用机制之一。     

survivin在二烯丙基二硫诱导HepG2细胞凋亡中的作用

目的:研究survivin在二烯丙基二硫(diallyl disulfide,DADS)诱导HepG2细胞凋亡中的作用。方法:MTT法检测细胞的生长活性;流式细胞仪检测细胞周期;RT-PCR法检测survivin mRNA水平;Western blot法检测survivin蛋白水平。结果:用药组HepG2细胞活性与正常组相比,随着药物浓度的增加(25,50,100,200μmol/l),分别下降了9．3%、10．4%、21．6%、31．2%,HepG2细胞凋亡率分别增加0．83%、1．97%、6．0%、9．9%,低浓度(25,50μmol/l)的DADS可以诱导survivin mRNA和蛋白表达升高,而高浓度的(100,200μmol/l)DADS可以降低survivin mRNA和蛋白表达。结论:DADS诱导HepG2细胞survivin表达增加,抵抗DADS诱导HepG2细胞的凋亡作用。     

人生存素survivin的克隆与分泌表达

旨在克隆人生存素( survivin)基因,并在原核系统中进行可溶性表达.采用RT-PCR方法从人乳腺癌细胞MCF-7中克隆survivin基因,将其重组到pAYZ表达栽体中,构建带有六聚组氨酸纯化标记的人survivin基因原核表达栽体pAYZ-survivin,将该载体转化大肠杆菌16C9进行表达.结果表明,成功克隆了survivin基因并构建了重组表达载体.融合蛋白主要以可溶性状态分泌到周质腔内存在.分离提取蛋白,HiTrap金属螯合柱进行亲和层析纯化,并经Western blot验证了高纯度survivin融合蛋白的表达.     

Prohibitin对非小细胞肺癌细胞增殖和凋亡的影响

目的:研究Prohibitin对非小细胞肺癌株A549和NCI-H460细胞增殖和凋亡的影响.方法:将针对Prohibitin的特异性的干扰片段瞬时转染非小细胞肺癌A549和NCI-H460细胞株,以瞬时转染与Prohibitin没有同源性的干扰片段的细胞作为阴性对照,通过免疫蛋白印迹检测各组细胞Prohibitin和Survivin蛋白的表达情况,通过MTT法检测各组细胞的增殖情况,通过流式仪检测各组细胞的凋亡率.结果:针对Prohibitin基因设计的siRNA片段特异性地沉默该基因的表达,与对照组相比较,干扰组的细胞的增殖活性明显增强.同时与凋亡密切相关的Survivin的表达在沉默掉prohibitin后,在A549和NCI-H460中分别降低了46.3%和54.5%.而干扰prohibitin后导致A549细胞的凋亡率上升了约2%.结论:Prohibitin能显著抑制非小细胞肺癌A549和NCI-H460细胞的增殖,而对凋亡的影响可能并不是通过survivin介导的.     

应用组织芯片技术研究Survivin基因蛋白在前列腺肿瘤组织中的表达及其意义

目的:应用组织芯片技术分析Survivin基因蛋白在人类前列腺癌组织、前列腺正常组织及前列腺良性痛变组织中的表达情况.方法:采用兔抗人survivin单克隆抗体的免疫组织化学ABC法,研究Survivin在不同前列腺组织的表达,并分析Survivin在不同前列腺组织中的表达差异.结果:免疫组化结果显示,前列腺癌组织与前列腺良性病变组织及正常前列腺组织中Survivin的表达相比呈显著性差异(P<0.05).结论:Survivin在前列腺癌组织中呈高表达,提示其可能对前列腺癌的发生或发展有重要作用.     

靶向VEGF小干扰RNA协同5-FU诱导人乳腺癌细胞MCF-7凋亡机制的研究

探讨慢病毒介导的靶向VEGF小干扰RNA联合应用化疗药物5 FU诱导人乳腺癌细胞MCF-7凋亡的机制。以携带VEGF siRNA的慢病毒载体感染MCF-7细胞,应用RT-PCR和Western blot分别检测各组VEGF mRNA、VEGF蛋白及凋亡相关蛋白的表达,流式细胞术检测细胞凋亡。结果表明,慢病毒VEGF siRNA干扰组细胞VEGF mRNA和蛋白表达水平明显低于对照组,凋亡相关蛋白P53及P21表达上调,而SIRT1、Bcl-2及Survivin表达下调。流式细胞术检测显示慢病毒干扰组及5-FU组细胞凋亡率显著升高,联合治疗组的协同作用更为明显。上述结果表明：慢病毒介导的RNA干扰能明显抑制MCF-7细胞VEGF的表达,通过下调SIRTI蛋白的表达,导致P53蛋白表达上调,并调控其下游P21、bcl-2和Survivin的表达,从而诱导MCF-7细胞的凋亡,并且提高了MCF-7对5-FU的敏感性。     

High-level expression, purification and pro-apoptosis activity of HIV-TAT-survivin (T34A) mutant to cancer cells in vitro

Survivin, a novel member of the IAP family, was observed to express in the most common human cancers. Anti-cancer therapy targeting survivin had drawn considerable attention. This study focused on high-level expression of recombinant protein TAT-survivin (T34A) mutant in E. coli, purification and bioactivity of pro-apoptosis to various cell lines in vitro. The cDNA encoding survivin was cloned by RT-PCR from breast cancer cell lines B-cap37. After PCR site-directed mutagenesis and construction of expression vector pRSET-B-TAT-survivin (T34A), targeted TAT-survivin (T34A) protein was expressed highly in E. coli BL21 (DE3) by 0.5mM IPTG induction and its yield could reach 650 mg/l in fermentation culture. The fusion protein in a form of inclusion body was then solubilized, refolded and purified to a purity of 98% by cation exchange chromatography and size-exclusion chromatography. Four hundred and eighty milligrams protein of interest was obtained in per liter fermentation culture. This showed that the efficient procedures of large-scale expression and purification were successful for the mass production of the recombinant protein. Pro-apoptosis effects of target protein on four cancer cell lines and one normal cell line from human were confirmed by the change of morphology, and pro-apoptosis activity was evaluated by MTT, fluorescent staining of nuclei and flow cytometry assay. Results indicated that B-cap37 and SW1990 were very sensitive to TAT-survivin (T34A) protein. This finding revealed the recombinant protein was promising as an anti-cancer drug.     

重组HIV-TATm-Survivin(T34A)蛋白制备及其促癌细胞凋亡活性研究

从人乳腺癌细胞系B-Cap-37中克隆出Survivin的cDNA,并对其中编码34位Thr的密码子定点突变为Ala的密码子后,经一系列基因操作方法将天然HIV-TAT转导肽的突变体基因HIV-TATm引入Survivin(T34A)基因的5′端,正确构建了表达载体pRSET-B-HIV-TATm-Survivin(T34A),经转化E.coliBL21(DE3)后诱导表达,目的蛋白质以包涵体形式表达,占菌体总蛋白的45%。经3.7L发酵罐分批发酵可收获650mg/L的包涵体,经阳离子交换、凝胶层析分离和柱上复性与透析,得到纯度达96%以上的可溶性目的蛋白HIV-TATm-Survivin(T34A)。目的蛋白对人乳腺癌细胞B-Cap-37、人胰腺癌细胞SW1990和人肝癌细胞SSMC-7721作用4h后有在细胞形态上呈现出显著的凋亡特征,而对人宫颈癌细胞系Hela不敏感,对正常的人内皮细胞系EVC-304未见明显影响。作用24h时MTT法检测显示,120μg/mL目的蛋白对SW1990、B-Cap-37、SSMC-7721和Hela细胞的抑制率分别达到89%、63%、59.5%和39%,且具有剂量依赖性。对最为敏感的SW1990和B-Cap-37以每孔60μg/mL终浓度的目的蛋白作用48h的流式细胞技术检测发现,凋亡率分别为25.6%和19.3%,与对照相比,实验组细胞出现明显的凋亡峰,细胞周期的分布发生明显的变化,65%以上的癌细胞被阻滞于G1期。体外实验结果显示重组目的蛋白具有较强的抑制癌细胞增殖和促进凋亡作用,预示着良好的抗癌前景。     

Construction, expression, and purification of HIV-TAT-survivin (T34A) mutant: a pro-apoptosis protein in Escherichia coli

As a novel member of the IAP family, survivin was observed to express in the most common human cancers. Anti-cancer therapy targeting survivin has drawn considerable attention. This report presented firstly construction of recombinant plasmid pRSET-B-TAT-survivin (T34A), expression in Escherichia coli, purification, renaturation, and bioactivity. The cDNA encoding survivin was cloned by RT-PCR from breast cancer cell lines B-cap37. Expression vector pRSET-B-TAT-survivin (T34A) was constructed by PCR after survivin was mutated by PCR site-directed mutagenesis. Recombinant TAT-survivin (T34A) protein was expressed highly in E. coli BL21 (DE3) by 0.5 mM IPTG induction and its yield could reach 650 mg/l in fermentation culture. The fusion protein in a form of inclusion body was then solubilized, refolded, and purified to a purity of 98% by cation exchange chromatography and size-exclusion chromatography. Four hundred and eighty milligrams protein of interest was obtained in per liter fermentation culture. The protein of interest was identified by SDS-PAGE and Western blot analysis, and great bioactivity of target protein to two cancer cell lines was confirmed by morphological changes and evaluated by MTT. The findings suggested that recombinant protein TAT-survivin (T34A) has a bright future in cancer therapy targeting towards survivin, and the efficient procedure of expression and purification may be useful for the mass production of this therapeutically important protein.     

中性白细胞抑制因子在大肠杆菌中的表达与纯化

利用PCR技术扩增编码钩虫中性白细胞抑制因子(NIF)成熟肽的cDNA,克隆于表达载体pET-21a( )。序列分析表明与献报道一致。经IPTG诱导,在大肠杆菌BL21(DE3)plys中实现高效可溶性表达。SDS—PAGE分析结果表明,外源蛋白(相对分子质量28900)约占全菌蛋白的20％。菌体用溶菌酶处理。上清经Q—Sepharose FF阴离子交换、羟基磷灰石层析、Sephacryl S-100凝胶过滤,得到纯度约95％的重组NIF。活性测定结果表明,大肠杆菌表达的重组NIF能有效地抑制中性白细胞粘附。这些结果为利用大肠杆菌制备重组NIF奠定了基础。     

重组GM-CSF/IL-3融合蛋白表达菌发酵研究

基因工程菌的发酵技术是基因工程药物大规模生产所必备的关键技术,本文对于重组ＧＭ－ＣＤＦ／ＩＬ－３融合蛋白表达菌株Ｅ．ｃｏｌｉ ＢＬ２１（ＤＥ３）（ｐＦｕ）的生长及产物表达规律进行了探索,在此基础上进行高密度发酵研究,真体最终发酵密度达ＯＤ６００值６０以上,目的产物占菌体总蛋白２５％以上。     

植原体免疫主导膜蛋白Imp基因原核表达载体构建及表达

旨在构建植原体免疫主导膜蛋白Imp基因原核表达载体,并进行初步表达。以重组克隆质粒pMD18-T-Imp为模板,PCR扩增Imp基因片段。构建表达载体pET-28a(+)-Imp,转化宿主菌E.coliBL21(DE3)。筛选阳性克隆,提取重组质粒作PCR鉴定、酶切鉴定及IPTG诱导表达鉴定。PCR及双酶切结果显示,重组质粒pET-28a(+)-Imp构建成功。经IPTG诱导BL21(pET-28a(+)-Imp)表达约20 kD的蛋白,与预期的携带6×His-Tag的目的蛋白(19.5 kD)大小相符,主要以包涵体形式存在。结果显示,构建的表达载体pET-28a(+)-Imp在E.coliBL21(DE3)中能够达一定量表达,为进一步纯化Imp蛋白奠定基础。     

以重组P-gp为抗原建立检测MDR 1抗体间接ELISA方法的研究

目的:构建MDR 1基因原核表达质粒,表达P-gp重组蛋白,建立检测MDR1抗体的间接ELISA方法。方法:利用重组PCR技术扩增MDR 1基因的1kb片段,克隆至pET-28b（＋）中,构建原核表达质粒pETP-gp,转染感受态菌BL21（DE3）和BL21（DE3）plyss;以E.coli高效表达的P-gp基因主要抗原编码区重组蛋白为抗原,以HRP标记的兔抗人IgG为二抗,建立间接ELISA检测方法。结果:正确构建了pETP-gp原核表达质粒,并可在E.coli中高效表达,表达蛋白可用作检测MDR 1抗体ELISA抗原。结论:成功表达出重组蛋白P-gp,建立了检测MDR 1抗体的间接ELISA方法。     

Stress-governed expression and purification of human type II hexokinase in Escherichia coli

The full encoding sequence for human type II hexokinase (HXK II) was cloned into the E. coli expression vector pET 21b and expressed as a C-terminally hexahistidine-tagged protein in the BL21 (DE3) strain. The IPTG-induced HXK II approximately accounted for 17% of the total E. coli proteins, and 81% of HXK II(6xHis) existed in inclusion bodies. To improve the production of soluble recombinant HXK II protein, in the functionally active form, we used low temperature, and the osmotic stress expression method. When expressed at 18 degrees C, about 83% of HXK II(6xHis) existed in the soluble fraction, which amounted to a 4.1-fold yield over that expressed at 37 degrees C. The soluble form of HXK II(6xHis) was also highly produced in the presence of 1 M sorbitol under the standard condition (37 degrees C), which indicated that temperature downshift and low water potentials were required to improve the yield of active recombinant HXK II protein. The expressed protein was purified by metal chelate affinity chromatography performed in an IDA Excellose column charged with Ni2+ ions, resulting in about 40 mg recombinant HXK II protein obtained with purity over 89% from 5 l of E. coli culture. The identity of HXK II(6xHis) was confirmed by Western blotting analysis. Taken together, using the stress-governed expression described in this study, human active HXK II can be purified in sufficient amounts for biochemical and biomedical studies.